News
Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic
Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the market, as the drugmaker expects to submit the drug for approval for weight loss by the end of the year.
Blue Cross Blue Shield of Massachusetts says it will soon stop covering popular drugs for weight loss, like Ozempic and ...
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Massachusetts' largest commercial health insurer is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for ...
Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...
People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...
Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback